Brief: Pharmather Provides Update On Product Pipeline
21/12/2021 12:38
Dec 21 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER PROVIDES UPDATE ON PRODUCT PIPELINE AND
EXPECTED
MILESTONES FOR 2022
* PHARMATHER HOLDINGS LTD - EXPECTED MILESTONES FOR 2022
INCLUDE
INITIATING PHASE 3 CLINICAL STUDY FOR KETAMINE TO TREAT
PARKINSON'S DISEASE
Source text for Eikon: ID:nGNX7zrfXY
Further company coverage: PHRM.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application